BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 29689435)

  • 1. Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC.
    Schild SE; Pang HH; Fan W; Stinchcombe TE; Vokes EE; Ramalingam SS; Bradley JD; Kelly K; Wang X
    J Thorac Oncol; 2018 Aug; 13(8):1171-1182. PubMed ID: 29689435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer.
    Schild SE; Fan W; Stinchcombe TE; Vokes EE; Ramalingam SS; Bradley JD; Kelly K; Pang HH; Wang X
    J Thorac Oncol; 2019 Feb; 14(2):298-303. PubMed ID: 30292852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
    Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
    Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Definitive chemotherapy and radiotherapy in patients with stage II non-small cell lung cancer: A population-based outcomes study.
    Sampath S; Hall M; Schultheiss TE
    Lung Cancer; 2015 Oct; 90(1):61-4. PubMed ID: 26231092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation.
    Grills IS; Yan D; Martinez AA; Vicini FA; Wong JW; Kestin LL
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):875-90. PubMed ID: 14529795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IMRT and 3D conformal radiotherapy with or without elective nodal irradiation in locally advanced NSCLC: A direct comparison of PET-based treatment planning.
    Fleckenstein J; Kremp K; Kremp S; Palm J; Rübe C
    Strahlenther Onkol; 2016 Feb; 192(2):75-82. PubMed ID: 26438071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unresected stage III non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.
    Okawara G; Rusthoven J; Newman T; Findlay B; Evans W
    Cancer Prev Control; 1997 Aug; 1(3):249-59. PubMed ID: 9765750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent chemoradiotherapy with cisplatin and vinorelbine for stage III non-small cell lung cancer.
    Naito Y; Kubota K; Nihei K; Fujii T; Yoh K; Niho S; Goto K; Ohmatsu H; Saijo N; Nishiwaki Y
    J Thorac Oncol; 2008 Jun; 3(6):617-22. PubMed ID: 18520801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer.
    Feigenberg SJ; Hanlon AL; Langer C; Goldberg M; Nicolaou N; Millenson M; Coia LR; Lanciano R; Movsas B
    J Thorac Oncol; 2007 Apr; 2(4):287-92. PubMed ID: 17409799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer.
    Choy H; Nabid A; Stea B; Scott C; Roa W; Kleinberg L; Ayoub J; Smith C; Souhami L; Hamburg S; Spanos W; Kreisman H; Boyd AP; Cagnoni PJ; Curran WJ
    J Clin Oncol; 2005 Sep; 23(25):5918-28. PubMed ID: 16135463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognosis of locally advanced non small cell lung cancer treated with three dimentional conformal radiotherapy].
    Zhu XZ; Wang LH; Ou GF; Zhou ZM; Chen DF; Xiao ZF; Feng QF; Zhang HX; Wang M; Yin WB
    Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):748-53. PubMed ID: 18396686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary results of a phase II study of weekly paclitaxel (PTX) and carboplatin (CBDCA) administered concurrently with thoracic radiation therapy (TRT) followed by consolidation chemotherapy with PTX/CBDCA for stage III unresectable non-small-cell lung cancer (NSCLC).
    Kaplan B; Altýnbas M; Eroglu C; Karahacioglu E; Er O; Ozkan M; Bilgin M; Canoz O; Gulmez I; Gulec M
    Am J Clin Oncol; 2004 Dec; 27(6):603-10. PubMed ID: 15577439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06.
    Komaki R; Scott C; Lee JS; Urtasun RC; Byhardt RW; Emami B; Andras EJ; Asbell SO; Rotman M; Cox JD
    Am J Clin Oncol; 1997 Oct; 20(5):435-40. PubMed ID: 9345325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved survival with dose-escalated radiotherapy in stage III non-small-cell lung cancer: analysis of the National Cancer Database.
    Brower JV; Amini A; Chen S; Hullett CR; Kimple RJ; Wojcieszynski AP; Bassetti M; Witek ME; Yu M; Harari PM; Baschnagel AM
    Ann Oncol; 2016 Oct; 27(10):1887-94. PubMed ID: 27502703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
    Sher DJ; Koshy M; Liptay MJ; Fidler MJ
    Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer.
    Sekine I; Nokihara H; Sumi M; Saijo N; Nishiwaki Y; Ishikura S; Mori K; Tsukiyama I; Tamura T
    J Thorac Oncol; 2006 Oct; 1(8):810-5. PubMed ID: 17409964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial.
    Movsas B; Hu C; Sloan J; Bradley J; Komaki R; Masters G; Kavadi V; Narayan S; Michalski J; Johnson DW; Koprowski C; Curran WJ; Garces YI; Gaur R; Wynn RB; Schallenkamp J; Gelblum DY; MacRae RM; Paulus R; Choy H
    JAMA Oncol; 2016 Mar; 2(3):359-67. PubMed ID: 26606200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies.
    Stinchcombe TE; Zhang Y; Vokes EE; Schiller JH; Bradley JD; Kelly K; Curran WJ; Schild SE; Movsas B; Clamon G; Govindan R; Blumenschein GR; Socinski MA; Ready NE; Akerley WL; Cohen HJ; Pang HH; Wang X
    J Clin Oncol; 2017 Sep; 35(25):2885-2892. PubMed ID: 28493811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer.
    Kim TY; Yang SH; Lee SH; Park YS; Im YH; Kang WK; Ha SH; Park CI; Heo DS; Bang YJ; Kim NK
    Am J Clin Oncol; 2002 Jun; 25(3):238-43. PubMed ID: 12040280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.